On August 9, 2023, Burning Rock (NASDAQ/LSE: BNR) announced a China collaboration with AstraZeneca (NASDAQ/LSE/STO: AZN). As part of the collaboration, Burning Rock will leverage its leading detection technologies and high-quality, standardized testing capabilities to develop and commercialize companion diagnostics (CDx) to support the roll-out of key clinical trials in AstraZeneca’s breast and prostate cancer development programs in China. This collaboration aims to help advance clinical research and future commercial opportunities.
Precision medicine has entered a new era, and the synergy of drugs and diagnostics is essential. Next-generation sequencing (NGS) can achieve precise detection of multiple genetic mutations, various variant types, and complex molecular markers. Currently, based on its leading NGS research and detection technology, Burning Rock has established multiple authoritative certification laboratories in China and the United States, a global CDx registration pipeline, and a complete drug development biomarker solution loop. This enables effective support for global pharmaceutical companies to conduct clinical projects and CDx development and filing in multiple locations simultaneously, consistently as an alternative, and efficiently, promoting comprehensive industry development.
Burning Rock’s founder and CEO, Han Yusheng, said: “We are pleased to partner with one of the world’s leading biopharmaceutical company, AstraZeneca, on companion diagnostics. We believe that this collaboration will leverage the capabilities & expertise of both organizations in drug and CDx development to provide matching CDx products during the drug development process. Through this collaboration, we look forward to reinforcing the value of precision medicine and brining innovative medicines to patients with breast and prostate cancer based upon their individual tumor profile. ”
About Burning Rock
Burning Rock Biotech Limited (NASDAQ/LSE:BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of 1) NGS-based therapy selection testing for late-stage cancer patients, 2) Global pharmaceutical services on biomarker detection and companion diagnostics developing, and 3) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.